MeiraGTx Cash Flow Statement
NASDAQ: MGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
10.69+0.19 (+1.81%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MeiraGTx free cash flow
In fiscal 2025, MeiraGTx generated -$46.4 million of operating cash flow and spent $3.8 million on capital expenditures. That left free cash flow of -$50.2 million, a free-cash-flow margin of -61.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
MeiraGTx cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20212022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M | -57.99M | -54.75M | -82.87M | -31.04M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 12.54M | 12.83M | 13.73M | 8.72M | 7.87M | 4.17M | 2.24M | 2.05M | 679.18K |
| Stock-Based Compensation | 22.11M | 25.19M | 27.72M | 28.62M | 20.78M | 18.42M | 15.93M | 17.88M | 2.96M |
| Change in Working Capital | -8.63M | 23.44M | -5.56M | 427.00K | 13.98M | -11.83M | 92.25M | 410.07K | 9.70M |
| Operating Cash Flow | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M | -63.97M | 20.04M | -58.89M | -18.06M |
| Capital Expenditures | -3.83M | -4.96M | -20.17M | -44.96M | -46.35M | -20.92M | -8.98M | -11.26M | -10.54M |
| Investing Cash Flow | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M | -37.02M | -9.37M | -11.26M | -10.54M |
| Financing Cash Flow | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M | 82.73M | 148.23M | 130.04M | 19.34M |
| Net Change in Cash | -38.19M | -26.48M | 12.69M | -22.86M | -70.54M | -18.26M | 158.91M | 59.89M | -9.25M |
| Free Cash Flow | -50.19M | -109.45M | -125.54M | -118.06M | -56.88M | -84.89M | 11.06M | -70.15M | -28.59M |
This table shows 9 annual periods of MeiraGTx's cash flow statement, from FY 2025 back to FY 2017, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MGTX's reporting calendar. What is a cash flow statement?